Buradasınız

KARACİĞERVE BÖBREK DOKUSUNDA RANİTİDİNİN DEJENERATİF ETKİSİNE KARŞI KARNİTİNİN KORUYUCU ROLÜ

Protective role of carnitine against degenerative effect of ranitidine in liver and kidney tissues

Journal Name:

Publication Year:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Ranitidine are widely prescribed H2 receptor antagonists used in treatment of acid-peptic disorder ranitidine shows hepatotoxic effect in the liver and the kidney. Therefore, carnitine administration can be considered when the degeneration is limited to the liver and the kidney. In this study ranitidine-induced liver and kidney damages were investigated in adult Wistar rats. We utilized five groups as the control; ranitidine (10 mg/mg i.m.J for two months; ranitidine (10 mg/mg i.m.)+ carnitine (20mg/kg) mixed with water for one month; ranitidine+carnitine at the same doses for two months, and normal diet following ranitidine treated for two months, each group having 6 animals. In the hepatotoxity induced by ranitidine, there were Kupffer cell proliferation, fatty infiltration, mononuclear cell infiltration. In the cortex and medulla of the kidney there were inflammatory interstitial bleeding areas. In the groups treated with carnitine, the prognosis of the liver and the kidney could not be significantly changed. However, degeneration had been significantly decreased in both of the groups treated with carnitine. The tissues in the group having normal diet following ranitidine administration have shown similar changes to the groups with carnitine administration.
Abstract (Original Language): 
Ranitidin mide ülserlerinin tedavisinde yaygın olarak kullan/an H2 reseptör blokörüdür. Ranitidin karaciğerde hepatotoksik, böbrekte nefrotoksik etki gösterir. Bununla birlikte, kam/tin uygulamasının, karaciğer ve böbrekte dejenerasyonu azaltacağı düşünülür. Mevcut çalışmada, ranitidinle indüklenmiş karaciğer ve böbrek hasarına karşı karnitin'in etkisi ergin Wistar sıçanlarda araştırıldı. Beş gruptan ibaret her bir grupta altı adet hayvan olmak üzere, kontrol; iki ay ranitidin (10 mg/mg i.m.), bir ay ranitidin (10 mg/mg i.m.)+ suya karıştırılmış olarak Kam/tin (20 mg/kg); iki ay normal diet gruplarına ayrıldı. Ranitidinle indüklenmiş hepatotoksisiteye bağlı olarak karaciğerde, Kupffer hücre proliferasyonu, yağlanma ve mononükleer hücre infiltrasyonları gözlendi. Böbrek korteks ve medüllasında ise belirgin mononükleer hücreli inflamatuvar interstisyel infitrasyon ve interstisyel kanama alanlarının oluşumu mevcuttu. Kam/tin uygu/anan gruplarda, karaciğer ve böbreğin prognozu tamamen önemli ölçüde değiştirilemedi, hasar kaldı. Buna rağmen kam/tin uygu/anan her iki grupta dejenerasyon önem/i ölçüde azalmıştı. Ranitidin uygulamasını tak/ben normal diyetle beslenen grupta ise dokular kam/tin uygu/anmış gruplara benzer bulgular gösterdi.
211-216

REFERENCES

References: 

1. Breen KJ, Bury R, Desmond PV, Masheford ML, Morphett B, Westwood B, Shaw RG. Effects of cimetidine and ranitidine on hepatic drug metabolism. Clin Pharmacol 1982;31 (3):297-3QQ.
2. Feeley J, Guy E. Ranitidine laso reductions liver blood flow. Lancet. 1982; 1: 169.
3. Gang DC, Weidler DJ, Baltodono N, Eshelman FN. Pharmocokinetcs of ranitidine a new histamine H2-receptor blocker. Abstract. Clin Pharmacol and Therapeutics. 1981;29:248.
4. Peden NR, Saunders JHB, Wormsley KG. Inhibition of pentagastrin-stimulated and nocturnal gsstric secretion by ranitidine. Lancet. 1979;1:690-2.
5. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drug 1982;24:267-303.
6. Lebert PA, Mahon WA, MacLeod SN, Soldin SJ, Fenje P, Vandenberghe HM. Ranitidine kinetics and dynamics. II. Intravenous dose studies and comparison with cimetidine. Clin Pharmacol 1981;30 (4): 545-50.
7. Barr GD, Piper DW. Possible ranitidine hepatitis. Med J Aust. 1981;2:421.
8. Gaughan WJ, Sheth RV, Francos GC, Michael HJ, Burke JF. RanitJdine-induced acute interstitial nephritis with epithelial cell foot process fusion. Am J Kidney Dis 1993;22:337-340.
9. Boehm KA, Helms RA. Hospital Pharmacy 1993;28:843, 847-50.
10. Bremer J. Carnitine metabolism and functions. 1983;Vol. 63.
11. Amodio P, Angeli P, Merkel C, Menon F, Gatta A. Plasma Carnitine levels in liver cirrhosis: Relationship with nutritional status and liver damage. J Clin Chem Biochem 1990;28:619-26.
12. Kayaalp
O
. Tıbbi Farmakoloji, Cilt III. II. Baskı, Ankara, 1983, 2281-7. Nüve Matbaası.

Thank you for copying data from http://www.arastirmax.com